ProCE Banner Activity

Expert Commentary and Insight on Key Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Conference Coverage
Clinical Thought

In this commentary, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, address some of the most pressing questions on key data for gynecologic cancers presented at the 2023 SGO Annual Meeting, including practice-changing results for endometrial cancer, novel combinations in low-grade serous ovarian cancer, and studies exploring sequencing immunotherapy and chemoradiation in cervical cancer.

Released: May 16, 2023

Share

Faculty

Linda R. Duska

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Faculty Disclosure

Primary Author

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

Linda Duska, MD, MPH, FACOG, FACS, FASCO: researcher: Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax.

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

David Scott Miller, MD, FACOG, FACS: consultant/advisor/speaker: Agenus, AstraZeneca, Asymmetric, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, Immunogen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millenium, NVision, Novartis, Pfizer, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic; researcher: EMD Serono Research & Development, Leap.